Drug Profile

AXR 159

Alternative Names: AXR-159

Latest Information Update: 12 Dec 2022

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator AxeroVision
Class Eye disorder therapies
Mechanism of Action Alpha4beta7 integrin antagonists; Integrin alpha4beta1 antagonists

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity Yes

12 Dec 2022 AXR 159 is still in phase-II trials for Dry eyes in USA (AxeroVision pipeline; December 2022)
13 Jan 2021 AxeroVision completes a phase II trial in Dry eyes in USA (NCT03598699)
09 Jul 2018 Phase-II clinical trials in Dry eyes in USA (Ophthalmic) (NCT03598699)

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com